Ionis Pharmaceuticals has matured into a fully integrated commercial-stage biotech firm with seven marketed RNA-targeted therapies addressing rare diseases. However, revenue fell by over 10% year-over-year in 2025, partially due to lingering commercialization investments and competitive pressures. The company’s operating losses more than doubled, reflecting significant spending on scaling internal sales infrastructure for independent launches like TRYNGOLZA and DAWNZERA. Regulatory advances, such as EU approval of DAWNZERA and FDA priority review for Olezarsen, provide potential growth catalysts. Still, ongoing risks around market acceptance, reimbursement hurdles, and manufacturing remain substantial headwinds.